Document is current
Any future updates will be listed below
-
Authors
Phan, Thanh T. N.
Thiono, Devina J.
Hvasta, Matthew G.
Shah, Ruby P.
Ajo, Gisselle Prida
Huang, Wei-chiao
Lovell, Jonathan F. https://orcid.org/0000-0002-9052-884X
Tian, Shaomin
de Silva, Aravinda M. https://orcid.org/0000-0003-3317-5950
Kuhlman, Brian https://orcid.org/0000-0003-4907-9699
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI161025, 1U19AI181960, R01AI161025)
- License Information
-
More Information
Article History
Received: 15 September 2024
Accepted: 27 May 2025
First Online: 9 June 2025
Competing interests
: W.H. and J.L. hold interest in POP Biotechnologies, which is commercializing the CPQ liposome technology employed in this study. T.P., A.S., and B.K. are inventors on a patent application describing amino acid mutations that stabilize the E dimer from dengue virus. These mutations are used in this study. All other authors describe no competing interests.
